Which Is the Better Stock Buy?
Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified…
Eli Lilly’s Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief
Retatrutide’s recent trial results suggest it may be even better than Eli Lilly’s already approved GLP-1 medication, tirzepatide.…
How Will Mounjaro and Zepbound Sales Aid LLY’s Upcoming Q4 Results?
Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its…
The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth
jetcityimage / iStock Editorial via Getty Images Lilly posted 53.9% revenue growth and 480% net income growth driven…
Vanda Jumps 21% After FDA Approves Motion Sickness Therapy
This article first appeared on GuruFocus. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped roughly 21% in premarket trading after the U.S.…
Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access
This article first appeared on GuruFocus. Weight-loss drugs known as GLP-1s are increasingly reshaping healthcare and the pharmaceutical…
China’s new commercial insurance model could broaden access to Alzheimer’s drugs
ChiÂna’s new comÂmerÂcial inÂsurÂance forÂmuÂlaÂry looks to exÂpand paÂtient acÂcess to Alzheimer’s disÂease medÂiÂcines from Eli LilÂly and…
US approves Wegovy pill, giving Novo Nordisk an edge in obesity drug competition
US regulators have given the green light to a pill version of the blockbuster weight-loss drug Wegovy, the…
Novo’s Wegovy pill to test demand from consumers with cash
LONDON, Dec 23 (Reuters) – Novo Nordisk’s newly approved weight-loss pill version of Wegovy will be a test…
Eli Lilly’s pill solves the biggest problem with weight loss
Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly…
Eli Lilly Scores Another Major Win: Time to Buy?
Eli Lilly’s next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should…
Better Buy in 2026: Pfizer or Eli Lilly?
Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer’s…